SEATTLE, April 07, 2020 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global anti-malaria drugs market was valued at US$ 839.1 million in 2019 and is expected to exhibit a CAGR of 4.47% during the forecast period (2019-2027).
Key Trends and Analysis of the Global Anti-malaria Drugs Market:
The increasing regulatory approvals for drugs is expected to drive growth of the anti-malaria drugs market. For instance, in August 2018, 60 Degrees Pharmaceuticals (60P), Washington, D.C. received the U.S. FDA approval for Arakoda (tafenoquine) for the prophylaxis of malaria in patients aged 18 years and older. Moreover, for same drug molecule (Krintafel (tafenoquine)), GSK and Medicines for Malaria Venture (MMV) also received the U.S. FDA approval in 2018.
Request for Sample PDF copy @ https://www.coherentmarketinsights.com/insight/request-sample/3726
Moreover, high prevalence of malaria in low and middle income countries is expected to drive growth of the anti-malaria drugs market. For instance, according to WHO, in 2017, around 3 million cases of malaria were diagnosed in India. Moreover, WHO stated that in 2019, India accounted for 21% of total deaths in South-east Asia region. Furthermore, as per WHO data, in 2018, five countries including Nigeria (25%), Democratic Republic of the Congo (11%), Mozambique (5%), India (4%), and Uganda (4%) accounted for a total 50% of total global burden of malaria.
Launching of anti-malaria drugs in the malaria affected areas such as African countries such as Uganda and other South-east Asian countries is expected to drive growth of the anti-malaria drugs market. For instance, in April 2019, Shin Poong Pharmaceutical Co.Ltd, South Korea, and Medicines for Malaria Venture (MMV) launched Pyramax, an anti-malarial drug combination of pyronardine and artesunate, in Uganada.
Key Market Takeaways:
- The global anti-malaria drugs market is expected to witness a CAGR of 4.4% over the forecast period (2019 – 2027), owing to new product developments and increasing demand for antimalarial drugs in the WHO registered malaria affected areas such as Sub-Saharan Africa and South–east Asia regions
- Among drug class, aminoquinoline segment is expected to witness significant growth in the anti-malaria drugs market over the forecast period, owing to increasing number of product approvals and launches for this drug in this drug class.
Major players operating in the global anti-malaria drugs market include—
Ipca Laboratories Ltd., Zydus Cadila, Merck KGaA, Pfizer, GlaxoSmithKline Plc., Cipla Ltd, Ranbaxy Laboratories, Novartis AG, Alvizia Health Care, Bayer AG, and Roche Inc
Buy this Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/3726
Market Segmentation:
- Global Anti-malarial Drugs Market, By Drug Class:
- Aminoquinolines
- Quinoline-methanol (4-quinolinemethanols)
- Cinchona Alkaloids
- Biguanides
- Sulfonamides and sulfones
- Others
- Global Anti-malarial Drugs Market, By Route of Administration:
- Oral
- Injectable
- Global Anti-malarial Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Anti-malarial Drugs Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Country:
- North America
-
-
-
- Online Pharmacies
-
-
-
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- Asia Pacific
Related Reports:
HYDROXYCHLOROQUINE MARKET
Hydroxychlorquine has exhibits the potential invitro activity against viruses including influenza, malaria, coronavirus, and many other diseases. The drug is under investigation to determine its efficacy for the treatment of novel coronavirus disease (COVID 19). According to the studies conducted in Wuhan, the body temperature recovery time and the cough remission time of coronavirus patients were significantly reduced with hydroxycloroquine and chloroquine treatment.
Read more @ https://www.coherentmarketinsights.com/market-insight/hydroxychloroquine-market-3727